Halfway Mark Reached in Optiscan Breast Cancer Study
Filed with ASX · · 6 pages · English
Summary by 6ix AI
The study, conducted in collaboration with The Royal Melbourne Hospital, is evaluating the effectiveness of two imaging devices during breast cancer surgeries. The results will support future U.S. FDA submissions for these devices, expected to be completed later in the year. CEO Dr. Camile Farah expressed pride in the study's progress and its potential to enhance surgical decision-making and patient outcomes.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Optiscan Imaging Limited on 6ix
Earlier from Optiscan Imaging
- Second Anniversary of Optiscan and Mayo Clinic Agreement
- Optiscan Receives $1.69m R&D Tax Refund
- Optiscan Submits InSpecta FDA Dossier
- Appendix 4D
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Optiscan Imaging
- Optiscan Launches InSpecta Device for Veterinary Medicine
- Head and Neck Study Progressing Ahead of Schedule
- Optiscan Signs New Research Agreement for Breast Study
- Preliminary Final Report
- Optiscan Initiates Head and Neck Cancer Study in the US
Follow Optiscan Imaging into a list and get an email when it puts out news.
Follow Optiscan Imaging